-
1
-
-
77955635233
-
-
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, CA: a cancer journal for clinicians 2010; 60:277-300.
-
(2010)
Cancer Statistics, CA: A Cancer Journal for Clinicians
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
3
-
-
38349167518
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
-
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242-5.
-
(2008)
J Clin Oncol
, vol.26
, pp. 242-245
-
-
Berthold, D.R.1
Pond, G.R.2
Soban, F.3
De Wit, R.4
Eisenberger, M.5
Tannock, I.F.6
-
4
-
-
0032784113
-
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
-
Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506-13.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2506-2513
-
-
Kantoff, P.W.1
Halabi, S.2
Conaway, M.3
Picus, J.4
Kirshner, J.5
Hars, V.6
-
5
-
-
8944220720
-
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
-
Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756-64.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1756-1764
-
-
Tannock, I.F.1
Osoba, D.2
Stockler, M.R.3
Ernst, D.S.4
Neville, A.J.5
Moore, M.J.6
-
6
-
-
29944434214
-
Therapeutic options in androgen-independent prostate cancer: Building on docetaxel
-
Petrylak D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU international 2005; 96:41-6.
-
(2005)
BJU International
, vol.96
, pp. 41-46
-
-
Petrylak, D.1
-
7
-
-
77951644363
-
Phase II trial of bevacizumab, thalidomide, docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer
-
Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, et al. Phase II trial of bevacizumab, thalidomide, docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:2070-6.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2070-2076
-
-
Ning, Y.M.1
Gulley, J.L.2
Arlen, P.M.3
Woo, S.4
Steinberg, S.M.5
Wright, J.J.6
-
8
-
-
4344682179
-
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
-
Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2532-9.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2532-2539
-
-
Dahut, W.L.1
Gulley, J.L.2
Arlen, P.M.3
Liu, Y.4
Fedenko, K.M.5
Steinberg, S.M.6
-
9
-
-
34547119271
-
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
-
Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110:556-63.
-
(2007)
Cancer
, vol.110
, pp. 556-563
-
-
Rosenberg, J.E.1
Weinberg, V.K.2
Kelly, W.K.3
Michaelson, D.4
Hussain, M.H.5
Wilding, G.6
-
10
-
-
73949098659
-
Multinational, doubleblind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial
-
Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, doubleblind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27:5431-8.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5431-5438
-
-
Sternberg, C.N.1
Petrylak, D.P.2
Sartor, O.3
Witjes, J.A.4
Demkow, T.5
Ferrero, J.M.6
-
11
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
-
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-54.
-
(2010)
Lancet
, vol.376
, pp. 1147-1154
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
Hansen, S.4
MacHiels, J.P.5
Kocak, I.6
-
13
-
-
50849088935
-
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
-
Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547-52.
-
(2008)
Ann Oncol
, vol.19
, pp. 1547-1552
-
-
Pivot, X.1
Koralewski, P.2
Hidalgo, J.L.3
Chan, A.4
Goncalves, A.5
Schwartsmann, G.6
-
14
-
-
59449102526
-
Phase i and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors
-
Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723-30.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 723-730
-
-
Mita, A.C.1
Denis, L.J.2
Rowinsky, E.K.3
Debono, J.S.4
Goetz, A.D.5
Ochoa, L.6
-
15
-
-
77957665460
-
Cabazitaxel in prostate cancer: Stretching a string
-
Dorff TB, Quinn DI. Cabazitaxel in prostate cancer: stretching a string. Lancet 2010; 376:1119-20.
-
(2010)
Lancet
, vol.376
, pp. 1119-1120
-
-
Dorff, T.B.1
Quinn, D.I.2
|